パラセタモール点滴静注の世界市場

パラセタモール点滴静注の世界市場は2030年までに8億6,650万米ドルに達する見込み

2024年に7億7,450万米ドルと推定されるパラセタモール点滴静注の世界市場は、分析期間2024～2030年にCAGR 1.9%で成長し、2030年には8億6,650万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである疼痛適応症は、CAGR 1.5%を記録し、分析期間終了時には5億9,280万米ドルに達すると予測されます。発熱・発熱表示セグメントの成長率は、分析期間中CAGR 2.9%と推定されます。

米国市場は推定2億1,100万米ドル、中国はCAGR 3.7％で成長予測

米国のパラセタモール点滴静注市場は、2024年に2億1,100万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億6,160万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは3.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7%と1.4%と予測されています。欧州では、ドイツがCAGR 1.0%で成長すると予測されています。

世界のパラセタモール点滴静注市場- 主要動向と促進要因のまとめ

パラセタモール点滴静注市場が着実な成長を遂げている理由とは？

静脈内（IV）パラセタモール市場は、病院や手術の現場における効果的な疼痛管理ソリューションに対する需要の高まりにより成長しています。パラセタモールの静脈内投与は、術後の疼痛緩和、外傷治療、発熱管理などに広く使用されており、経口鎮痛薬に代わる即効性を備えています。オピオイドに関連する中毒や呼吸抑制のリスクを伴わずに効果的な鎮痛を提供できることから、急性期医療の現場で好んで使用されています。

さらに、手術件数、救急外来受診件数、集中治療室（ICU）入室件数の増加が、静脈内パラセタモールへの需要に拍車をかけています。オピオイドの誤用に対する懸念が高まり、オピオイドの処方に対する規制が強化される中、ヘルスケアプロバイダーはオピオイドを使用しない疼痛管理の選択肢に目を向けつつあり、市場の拡大をさらに促進しています。

製剤とドラッグデリバリーの革新は、点滴用パラセタモールをどのように強化しているか？

パラセタモール静注用製剤の進歩により、薬物の安定性、バイオアベイラビリティ、輸液適合性が向上しています。投与効率を最適化し、投与回数を減らすために、徐放性製剤や高濃度製剤が開発されています。さらに、すぐに使える点滴用パラセタモール製剤は、病院のワークフローを合理化し、調製時間を短縮し、投薬ミスのリスクを最小限に抑えています。

もう1つの重要な技術革新は、パラセタモールの静脈内投与を、非オピオイド鎮痛薬とオピオイド鎮痛薬を組み合わせて鎮痛効果を高めながら副作用を最小限に抑える、マルチモーダル鎮痛プロトコールに統合することです。このアプローチは、外科手術の回復や重症患者管理で普及しつつあり、市場の成長に寄与しています。

非オピオイド疼痛管理へのシフトが市場需要を牽引？

オピオイド依存を減らすという世界の動きは、静脈内パラセタモール市場の主な促進要因です。政府やヘルスケア機関は、オピオイド危機と闘うため、非オピオイド代替疼痛管理を積極的に推進しています。静脈内パラセタモールは周術期治療や術後の回復に推奨されることが増えており、オピオイド鎮痛薬の必要性を減らしています。

さらに、手術後の回復促進（ERAS）プロトコルを重視する臨床ガイドラインでは、オピオイドを使用しない疼痛管理戦略の重要な要素として、パラセタモール静注が取り入れられています。このシフトにより、整形外科、心臓血管外科、消化器外科での採用が増加しています。

静脈内パラセタモール市場の成長を牽引しているのは？

静脈内パラセタモール市場の成長の原動力は、外科手術の増加、オピオイドを使用しない疼痛管理に対する需要の高まり、薬剤製剤とデリバリーシステムの進歩です。非オピオイド鎮痛薬に対する規制上の支援が、市場の採用をさらに加速させています。

さらに、病院インフラの拡大、クリティカルケアへのアクセスの改善、多剤併用型疼痛管理プロトコールへのパラセタモール静注の統合が需要を促進しています。ヘルスケアシステムが患者の安全性とオピオイド削減戦略を優先し続ける中、静脈内パラセタモール市場は持続的な成長が見込まれます。

セグメント

適応症（疼痛、発熱）、用途（外科手術、非外科手術）、最終用途（病院、診療所、その他）

調査対象企業の例

• Abbott Laboratories
• AdvaCare Pharma
• Anhui Shinecare Co., Ltd.
• Arrier Biotech Pvt Ltd
• Aurobindo Pharma
• B. Braun Melsungen AG
• Bristol-Myers Squibb Company
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Eurocrit Labs
• Gnova Biotech
• Granules India Limited
• Guangzhou Sinolead Biotech Co., Ltd.
• Hainan Seafort Healthcare Ltd
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Paracetamol IV Market to Reach US$866.5 Million by 2030

The global market for Paracetamol IV estimated at US$774.5 Million in the year 2024, is expected to reach US$866.5 Million by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Pain Indication, one of the segments analyzed in the report, is expected to record a 1.5% CAGR and reach US$592.8 Million by the end of the analysis period. Growth in the Pyrexia / Fever Indication segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$211.0 Million While China is Forecast to Grow at 3.7% CAGR

The Paracetamol IV market in the U.S. is estimated at US$211.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$161.6 Million by the year 2030 trailing a CAGR of 3.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Paracetamol IV Market - Key Trends & Drivers Summarized

Why Is the Paracetamol IV Market Experiencing Steady Growth?

The intravenous (IV) paracetamol market is growing due to the increasing demand for effective pain management solutions in hospital and surgical settings. IV paracetamol is widely used for post-operative pain relief, trauma care, and fever management, offering a fast-acting alternative to oral analgesics. Its ability to provide effective pain relief without the opioid-related risks of addiction and respiratory depression is making it a preferred choice in acute care settings.

Additionally, the rising number of surgeries, emergency room visits, and intensive care unit (ICU) admissions is fueling demand for IV paracetamol. With growing concerns about opioid misuse and regulatory restrictions on opioid prescribing, healthcare providers are turning to non-opioid pain management options, further driving market expansion.

How Are Formulation and Drug Delivery Innovations Enhancing IV Paracetamol?

Advancements in IV paracetamol formulations are improving drug stability, bioavailability, and infusion compatibility. Extended-release and high-concentration formulations are being developed to optimize dosing efficiency and reduce the frequency of administration. Additionally, ready-to-use IV paracetamol solutions are streamlining hospital workflows, reducing preparation time, and minimizing the risk of medication errors.

Another key innovation is the integration of IV paracetamol into multimodal analgesia protocols, which combine non-opioid and opioid analgesics to enhance pain relief while minimizing side effects. This approach is gaining traction in surgical recovery and critical care management, contributing to market growth.

Is the Shift Toward Non-Opioid Pain Management Driving Market Demand?

The global push to reduce opioid dependency is a major driver of the IV paracetamol market. Governments and healthcare institutions are actively promoting non-opioid alternatives for pain management to combat the opioid crisis. IV paracetamol is being increasingly recommended in perioperative care and post-surgical recovery, reducing the need for opioid analgesics.

Additionally, clinical guidelines emphasizing enhanced recovery after surgery (ERAS) protocols are incorporating IV paracetamol as a key component of non-opioid pain management strategies. This shift is leading to increased adoption in orthopedic, cardiovascular, and gastrointestinal surgeries.

What’s Driving the Growth of the IV Paracetamol Market?

The growth in the IV paracetamol market is driven by increasing surgical procedures, rising demand for opioid-free pain management, and advancements in drug formulation and delivery systems. Regulatory support for non-opioid analgesics is further accelerating market adoption.

Additionally, the expansion of hospital infrastructure, improved access to critical care, and the integration of IV paracetamol into multimodal pain management protocols are fueling demand. As healthcare systems continue to prioritize patient safety and opioid reduction strategies, the IV paracetamol market is expected to see sustained growth.

SCOPE OF STUDY:

The report analyzes the Paracetamol IV market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Pain Indication, Pyrexia / Fever Indication); Application (Surgical Application, Non-surgical Application); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• AdvaCare Pharma
• Anhui Shinecare Co., Ltd.
• Arrier Biotech Pvt Ltd
• Aurobindo Pharma
• B. Braun Melsungen AG
• Bristol-Myers Squibb Company
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• Eurocrit Labs
• Gnova Biotech
• Granules India Limited
• Guangzhou Sinolead Biotech Co., Ltd.
• Hainan Seafort Healthcare Ltd
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Paracetamol IV - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Preference for Fast-Acting Pain Relief in Postoperative Care Propels IV Paracetamol Demand
  • Surge in Hospital Admissions and Surgical Procedures Expands Institutional Use of Paracetamol IV
  • Improved Pain Management Protocols in Critical Care Units Drive Usage in Emergency Settings
  • Regulatory Approvals and WHO Guidelines Strengthen Business Case for Parenteral Formulations
  • Wider Acceptance in Pediatric and Geriatric Care Enhances Market Reach
  • Growing Demand for Non-Opioid Alternatives Throws Spotlight on IV Acetaminophen Use
  • Shorter Onset Time and Predictable Pharmacokinetics Drive Physician Preference Over Oral Dosage
  • Increased ICU and Emergency Department Budgets Support Premium Drug Administration Formats
  • Formulary Additions in Public Health Systems Expand Institutional Adoption
  • Improved Safety Profile Compared to NSAIDs Spurs Demand in Renal and GI Risk Patients
  • Advancements in IV Packaging and Portability Enhance Administration Efficiency
  • Pharmaceutical Partnerships and Hospital Supply Agreements Support Volume-Based Distribution
  • Greater Emphasis on Multimodal Pain Management Boosts Inclusion in Surgical Care Pathways
  • Global Tender-Based Procurement and Competitive Pricing Drive Adoption in Developing Markets
  • Post-Pandemic Recovery of Elective Surgeries Reignites Demand for IV Pain Relievers
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Paracetamol IV Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Paracetamol IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Paracetamol IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Paracetamol IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pain Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pain Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Pain Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Pyrexia / Fever Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Pyrexia / Fever Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Pyrexia / Fever Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Surgical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Surgical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Surgical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Non-surgical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Non-surgical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Non-surgical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: USA 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: USA 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 32: USA Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: Canada 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 59: China Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Paracetamol IV by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Paracetamol IV by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Paracetamol IV by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: France Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: France 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 77: France Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: France Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: France 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 83: Germany Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Germany Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Germany 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Germany Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Germany 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Italy Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Italy 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 95: Italy Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Italy Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Italy 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 101: UK Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: UK Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: UK 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: UK Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: UK 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 107: UK Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 110: Spain Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Spain Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Spain 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 113: Spain Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Spain Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Spain 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 119: Russia Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Russia Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Russia 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 122: Russia Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Russia Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Russia 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Rest of Europe 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Rest of Europe Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Rest of Europe 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Paracetamol IV by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Paracetamol IV by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Asia-Pacific 15-Year Perspective for Paracetamol IV by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Asia-Pacific Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Asia-Pacific 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 149: Australia Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Australia Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Australia 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 152: Australia Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Australia Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Australia 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 158: India Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: India Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: India 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 161: India Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: India Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: India 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 164: India Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 167: South Korea Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: South Korea Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: South Korea 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 170: South Korea Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: South Korea Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: South Korea 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Asia-Pacific Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Asia-Pacific Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 185: Latin America Recent Past, Current & Future Analysis for Paracetamol IV by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 186: Latin America Historic Review for Paracetamol IV by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Latin America 15-Year Perspective for Paracetamol IV by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 188: Latin America Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Latin America Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Latin America 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 197: Argentina Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Argentina Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Argentina 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 200: Argentina Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Argentina Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Argentina 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 206: Brazil Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Brazil Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Brazil 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 209: Brazil Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Brazil Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Brazil 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 215: Mexico Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Mexico Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Mexico 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 218: Mexico Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Mexico Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Mexico 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Latin America Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Latin America 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Latin America Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Latin America 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 233: Middle East Recent Past, Current & Future Analysis for Paracetamol IV by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 234: Middle East Historic Review for Paracetamol IV by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Middle East 15-Year Perspective for Paracetamol IV by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 236: Middle East Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Middle East Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Middle East 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 245: Iran Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Iran Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Iran 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 248: Iran Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Iran Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Iran 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 254: Israel Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Israel Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Israel 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 257: Israel Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Israel Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Israel 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Saudi Arabia Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Saudi Arabia 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Saudi Arabia Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Saudi Arabia 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 272: UAE Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: UAE Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: UAE 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 275: UAE Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: UAE Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: UAE 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Rest of Middle East Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Rest of Middle East 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Rest of Middle East Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Rest of Middle East 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Paracetamol IV Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 290: Africa Recent Past, Current & Future Analysis for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Africa Historic Review for Paracetamol IV by Indication - Pain Indication and Pyrexia / Fever Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Africa 15-Year Perspective for Paracetamol IV by Indication - Percentage Breakdown of Value Sales for Pain Indication and Pyrexia / Fever Indication for the Years 2015, 2025 & 2030
  • TABLE 293: Africa Recent Past, Current & Future Analysis for Paracetamol IV by Application - Surgical Application and Non-surgical Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Africa Historic Review for Paracetamol IV by Application - Surgical Application and Non-surgical Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Africa 15-Year Perspective for Paracetamol IV by Application - Percentage Breakdown of Value Sales for Surgical Application and Non-surgical Application for the Years 2015, 2025 & 2030
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Paracetamol IV by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Paracetamol IV by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION